Kymera Therapeutics Statistics Share Statistics Kymera Therapeutics has 70.16M
shares outstanding. The number of shares has increased by 2.14%
in one year.
Shares Outstanding 70.16M Shares Change (YoY) 2.14% Shares Change (QoQ) 0.27% Owned by Institutions (%) 90.84% Shares Floating 58.31M Failed to Deliver (FTD) Shares 84 FTD / Avg. Volume 0.01%
Short Selling Information The latest short interest is 7.57M, so 10.79% of the outstanding
shares have been sold short.
Short Interest 7.57M Short % of Shares Out 10.79% Short % of Float 13.38% Short Ratio (days to cover) 10.53
Valuation Ratios The PE ratio is -13.49 and the forward
PE ratio is -10.61.
Kymera Therapeutics's PEG ratio is
-0.74.
PE Ratio -13.49 Forward PE -10.61 PS Ratio 64.14 Forward PS 41.3 PB Ratio 3.61 P/FCF Ratio -14.56 PEG Ratio -0.74
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Kymera Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 7.53,
with a Debt / Equity ratio of 0.11.
Current Ratio 7.53 Quick Ratio 7.53 Debt / Equity 0.11 Debt / EBITDA -0.41 Debt / FCF -0.42 Interest Coverage -1050.74
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $226.31K Profits Per Employee $-1.08M Employee Count 208 Asset Turnover 0.05 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -11.32% in the
last 52 weeks. The beta is 2.18, so Kymera Therapeutics's
price volatility has been higher than the market average.
Beta 2.18 52-Week Price Change -11.32% 50-Day Moving Average 44.48 200-Day Moving Average 39.13 Relative Strength Index (RSI) 33.78 Average Volume (20 Days) 840,161
Income Statement In the last 12 months, Kymera Therapeutics had revenue of 47.07M
and earned -223.86M
in profits. Earnings per share was -2.98.
Revenue 47.07M Gross Profit 47.07M Operating Income -261.63M Net Income -223.86M EBITDA -216.24M EBIT -223.61M Earnings Per Share (EPS) -2.98
Full Income Statement Balance Sheet The company has 120.26M in cash and 87.76M in
debt, giving a net cash position of 32.49M.
Cash & Cash Equivalents 120.26M Total Debt 87.76M Net Cash 32.49M Retained Earnings -754.61M Total Assets 918.31M Working Capital 441.96M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -194.5M
and capital expenditures -12.84M, giving a free cash flow of -207.34M.
Operating Cash Flow -194.5M Capital Expenditures -12.84M Free Cash Flow -207.34M FCF Per Share -2.76
Full Cash Flow Statement Margins Gross margin is 100%, with operating and profit margins of -555.82% and -475.57%.
Gross Margin 100% Operating Margin -555.82% Pretax Margin -475.57% Profit Margin -475.57% EBITDA Margin -459.37% EBIT Margin -555.82% FCF Margin -440.47%
